Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q1 2025 · 10-Q
Revenue$1.14M$1.14M−17.0% vs Q1 2024 Net Income-$785.57K-$785.57KN/M vs Q1 2024 EPS Diluted-$0.24-$0.24N/M vs Q1 2024 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flow-$57,822N/M Free Cash Flowderived-$116,146— Margins · derivedGross margin-12.0%+9.2 pt vs Q1 2024
Operating margin-66.8%+0.1 pt vs Q1 2024
Net margin-69.1%+0.6 pt vs Q1 2024
ended Mar 31, 2025 · filed May 14, 2025 · 44 d after period end